BioCentury
ARTICLE | Clinical News

vTv starts Phase Ib/II trial of TTP399 for T1D

November 10, 2017 9:26 PM UTC

vTv Therapeutics Inc. (NASDAQ:VTVT) began the Phase Ib/II simplici-T1 trial to evaluate TTP399 (GKI-399) as an add-on to insulin therapy in about 126 adults with Type I diabetes.

The double-blind, U.S. trial's primary endpoint is the change in HbA1c from baseline at 12 weeks. Secondary endpoints include safety, total daily insulin dose, meal time bolus insulin, time in target glycemic range, hyperglycemic range and hypoglycemic range. In the first part of the trial, patients will receive up to 1,200 mg oral TTP399 once daily for 7 days. In the second part, patients will receive TTP399 or placebo for 12 weeks...

BCIQ Company Profiles

JDRF

vTv Therapeutics Inc.

BCIQ Target Profiles

Glucokinase (GCK) (GK)